Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE versus TRIPROLIDINE AND PSEUDOEPHEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE versus TRIPROLIDINE AND PSEUDOEPHEDRINE.
PROMETHAZINE HYDROCHLORIDE vs TRIPROLIDINE AND PSEUDOEPHEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
None Documented
None Documented
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Category A/B
Category A/B
Antihistamine / Antiemetic
Antihistamine